Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
274.29(c) 276.05(c) 278.64(c) 279.81(c) 282.15(c) Last
482 281 412 203 472 904 596 155 409 944 Volume
+0.99% +0.64% +0.94% +0.42% +0.84% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 15 205 M - -
Net income 2021 2 023 M - -
Net Debt 2021 3 725 M - -
P/E ratio 2021 13,6x
Yield 2021 -
Sales 2022 14 191 M - -
Net income 2022 1 245 M - -
Net Debt 2022 3 375 M - -
P/E ratio 2022 21,6x
Yield 2022 -
Capitalization 27 284 M 27 284 M -
EV / Sales 2021 2,04x
EV / Sales 2022 2,16x
Nbr of Employees 68 780
Free-Float 99,4%
More Financials
Company
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in... 
More about the company
Ratings of Laboratory Corporation of America Holdings
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
10/14LABORATORY OF AMERICA : Labcorp, Pillar Biosciences Sign Cancer Genomic Testing Deal
MT
10/12GeneCentric Therapeutics Collaborates with Labcorp to Develop Novel Rna-Based Oncology ..
CI
10/04LABORATORY OF AMERICA : Labcorp Receives Emergency Use Authorization for At Home Collectio..
AQ
10/01LABORATORY OF AMERICA : Home Collection Kit for Combined COVID-19, Flu Detection Receives ..
MT
10/01LABORATORY OF AMERICA : LabCorp Receives Emergency Use Authorization for At-Home Collectio..
MT
10/01LABCORP : Receives Emergency Use Authorization for At Home Collection Kit for Combined COV..
BU
10/01Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined CO..
CI
10/01Labcorp Gets EUA for At-Home Collection Kit for Covid-19/Flu Detection
DJ
10/01FISKER : Forms Specialty Engineering Unit in the UK
MT
09/28LABORATORY OF AMERICA : LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER 28,..
PU
09/28LABCORP : to Announce Third Quarter Financial Results on October 28, 2021
BU
09/17INSIDER SELL : Laboratory Corp Of America Holdings
MT
09/14LABORATORY OF AMERICA : Labcorp Completes Acquisition of Myriad Autoimmune's Vectra Testin..
AQ
09/14DASSAULT SYSTEMES : Labcorp Selects Medidata's Sensor Cloud to Expand Decentralized Clinic..
AQ
09/13LABORATORY OF AMERICA : LABCORP COMPLETES ACQUISITION OF MYRIAD AUTOIMMUNE'S VECTRA TESTIN..
PU
More news
News in other languages on LABORATORY CORPORATION OF AMERICA HOLDINGS
10/01Le kit de collecte à domicile de Laboratory Corp of America pour la détection combinée ..
10/01Fisker crée une unité d'ingénierie spécialisée au Royaume-Uni
09/17VENTE D'INITIÉS : Laboratory Corp Of America Holdings
09/13USA : obbligo vaccinale Biden mette alla prova fornitura test
06/07Warnungen vor Aufhebung der englischen Corona-Maßnahmen nehmen zu
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Stock Trading Strategies
LABORATORY CORPORATION OF AMERICA HOLDINGS - 06/30
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | LH | US50540R4092 | MarketScreener
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 282,15 $
Average target price 326,21 $
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors